Myeloproliferative Neoplasms Treatment Market By Drug (Jakfi) - Global Industry Insights, Trends, Outlook, And Opportunity Analysis, 2018-2026

  • To Be Published : Sep 2019 |
  • Format : CMI Insight PPT Format CMI Insight PDF Format

Myeloproliferative Neoplasms (MPNs) are a group of rare disease, in which the bone marrow produces excess blood cells. It can be white blood cells, red blood cells or platelets. The overproduction of blood cells by the bone marrow creates hindrance in the smooth flow of blood, which leads to various symptoms such as progressive cytopenias, cachexia and weight loss, splenomegaly, and blastic transformation. These conditions are developed gradually over a period of time. Most people are diagnosed after the age of 60 years, when they were accompanied by many other health issues, makes the treatment more difficult. The major symptoms associated with MPNs include bleeding problem, anemia, chest pain, fatigue, enlarged spleen, and weight loss. According to Annals of Hematology, approximately 90% of patients has experienced MPN-symptoms in past 12 months, wherein women are reported to have higher overall burden than men. The treatment for myeloproliferative neoplasms is mainly aimed to reduce the excess number of blood cells circulation. The concept of myleoproliferative disease was first given by hematologist Williom Dameshek in 1950. However, in 2008, World Health Organization (WHO) classified hematologic malignancies and renamed myloproliferative diseases to myeloproliferative neoplasms.  

Rising awareness of molecular abnormalities and cellular pathways involved in the pathogenesis of MPNs is expected to facilitate the development of novel drugs, propels the Myeloproliferative Neoplasms treatment market growth in the near future

Myeloproliferative neoplasm can significantly affect the quality of life of the patient. The complication and treatments as well as the physiological strains of cancer diagnosis can affect the physical and emotional wellbeing of patients. Effects of complication vary from depression, fatigue, pain or depression with suicidal ideation. Moreover, patients can experience few or no symptoms for a longer period of time. MPNs can be cured with proper monitoring and treatment. There has been a major revolution in the management of MPNs by introduction of JAK1 and JAK2 inhibitor and ruxolitinib. Ruxolitinib inhibits these two enzymes in order to manage MPNs. The drug has also been proven as an alternative therapy for the treatment of polycythemia vera. Further, the therapeutic armamentarium for MPN is still inadequate for normalization of life span, reduction in cardiovascular complications, and prevention of hematological progression.

Rising awareness of molecular abnormalities and cellular pathways involve in the pathogenesis of MPNs is expected to facilitate the development of clinical trials with novel drugs, either alone or in combination with ruxolitinib. Interferon (IFN) is a drug that has proven as an effective alternative for MPNs patients. Better understanding of its mechanism of action for MPNs could lead to better interferon compound and potential drugs. In 2017, MPN research foundation have initiated a MPNRF Interferon (IFN) multi-center project which is expected to bring together internationally recognized experts to determine cytokine-driven pathways that affect the path of the MPNs. It is a closely-related group of progressive blood cancer which is also among the lucrative opportunities for major players in the Myeloproliferative Neoplasms treatment market.

Collaboration among the biotech and pharmaceutical companies to identify new drugs for MPNs is expected to accelerate the market growth

Novartis AG and Incyte Corporation are among the key players in Myeloproliferative Neoplasms treatment market. According to MPN research foundation, biotech and pharmaceutical companies are expected to propel the demand for improved treatments and quickly connecting patients with latest treatment options. It is expected to lead developing relationships with biotech and pharmaceuticals companies to identify new areas for scientific exploration. For instance, Incyte Corporationis is developing inhibitor for Janus Kinase (JAK) and also focusing on the discovery, development, and commercialization of proprietary therapeutics globally.

Choose License Type

"How Can I Help You" ?

Finding it difficult to find the research that would cater to your business demands? Give us a chance to help you. One of our Research Consultants will connect to provide a customized solution.

[email protected]

Key Benefits

  • Custom Research Solution

    Talk to our research consultant to design an exclusive report as per your research needs.

  • Customer Fulfilment

    We aim to fulfil client's research demands with tailored research solutions.

  • Quick Turnaround Time Reports

    We aim to provide research studies in quickest turnaround time and in a much cost effective manner.

  • 360-degree Approach

    We cover each industry from supply and demand side with an aim to provide a most holistic research study.

  • Assured Quality

    We strive to provide most accurate and reliable research findings in our research reports.